Last 43.75 GBp
Change Today +1.25 / 2.94%
Volume 147.1K
FUM On Other Exchanges
Symbol
Exchange
London
OTC US
Stuttgart
As of 11:33 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

futura medical plc (FUM) Snapshot

Open
42.50 GBp
Previous Close
42.50 GBp
Day High
43.75 GBp
Day Low
42.50 GBp
52 Week High
01/2/14 - 80.00 GBp
52 Week Low
10/14/14 - 37.75 GBp
Market Cap
43.3M
Average Volume 10 Days
336.9K
EPS TTM
-0.04 GBp
Shares Outstanding
99.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FUTURA MEDICAL PLC (FUM)

Related News

No related news articles were found.

futura medical plc (FUM) Related Businessweek News

No Related Businessweek News Found

futura medical plc (FUM) Details

Futura Medical plc is engaged in the research and development of pharmaceutical drugs and medical devices in the United Kingdom. The company offers CSD500, a condom that incorporates an erectogenic compound to help men maintain a firmer erection during intercourse whilst wearing a condom; MED2002, a gel applied directly to the penis for the treatment of male erectile dysfunction; and PET500, a topical spray that enables men to prolong their sexual experience. Its pain relief management products, such as TPR100 and TIB200 incorporates a non-steroidal anti-inflammatory drug; and SPR300 a topical gel combines methyl salicylate and menthol. The company is headquartered in Guildford, the United Kingdom.

6 Employees
Last Reported Date: 03/28/14

futura medical plc (FUM) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 199.8K GBP
Finance Director, Secretary, Financial Contro...
Total Annual Compensation: 129.7K GBP
Chief Scientific Officer and Adviser to the B...
Total Annual Compensation: --
Chief Development Officer and Executive Direc...
Total Annual Compensation: 165.1K GBP
Compensation as of Fiscal Year 2013.

futura medical plc (FUM) Key Developments

Futura Medical plc Signs an Exclusive Licensing Agreement with Kwang Dong Pharmaceutical Co Ltd

Futura Medical plc announced that it has signed an exclusive licensing agreement with Kwang Dong Pharmaceutical Co Ltd. (Kwang Dong Pharmaceutical) for the marketing and distribution of CSD500, Futura's novel condom, in South Korea. Under the terms of the agreement, Kwang Dong Pharmaceutical will hold exclusive rights to market and distribute CSD500 in South Korea. Financial details are not being disclosed although Futura will receive an upfront payment and royalties on all product sales along with certain minimum performance guarantees.

Futura Medical plc Launches New Condom in Netherlands and Belgium

Futura Medical plc has launched a new condom CSD500 in the Netherlands and Belgium under the company's brand Blue Diamond. The launch of CSD500 in these two countries is in line with Futura's strategy of licensing the product on a territorial basis to create a strong global distribution platform of companies, using either their own condom brand or Blue Diamond brand. Bizzy Diamond, a Dutch condom distributor founded in 2003, will market Blue Diamond online using a social media campaign to generate awareness of the brand. CSD500 contains Futura's erectogenic gel Zanifil and benefits from three marketing claims, which have been clinically proven and approved by EU regulatory authorities: the maintenance of a firmer erection, maximised penile size and a longer lasting sexual experience for women.

Futura Medical plc Announces Unaudited Group Earnings Results for the Six Months Ended June 30, 2014

Futura Medical plc announced unaudited group earnings results for the six months ended June 30, 2014. For the period, the company reported net loss of £1.45 million compared to £0.88 million a year ago. Revenue was £2,262 compared to £320,513 a year ago. Operating loss was £1,651,772 compared to £1,037,700 a year ago. Loss before tax was £1,639,295 compared to £1,031,870 a year ago. Total comprehensive loss for the period attributable to owners of the parent company was £1,446,337 compared to £884,990 a year ago. Loss per share was 2.77 pence compared to 1.14 pence a year ago. Net cash used in operating activities was £1,308,901 compared to £764,123 a year ago. Purchase of plant and equipment was £1,592 compared to £2,398 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FUM:LN 43.75 GBp +1.25

FUM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FUM.
View Industry Companies
 

Industry Analysis

FUM

Industry Average

Valuation FUM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 603.4x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 746.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FUTURA MEDICAL PLC, please visit www.futuramedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.